Objective To observe the therapeutic effects and safety of Entecavir and Telbivudine on child-pugh B grade patients with hepatitis B-induced cirrhosis. Methods 70 child-pugh B grade patients with hepatitis B-induced cirrhosis were randomly divided into Entecavir group and Telbivudine group. There were 35 cases in each group. The patients were treated for 48 weeks, then analyze the therapeutic effects and datas of etiology and adverse reaction of the patients with laboratory Diagnosis and molecular biology analysis. Results After 48 weeks treatment , the child-pugh scores and HBV-DNA levels were lower significantly than pretherapy in Entecavir group and Telbivudine group (P0.05). The rates of serum HBV-DNA undetectable were 91.4% and 85.7% in the two groups respectively. At 48 weeks, the rates of HBeAg seroconversion were 22.2% and 28.6%. But there were not obviously differencies between Entecavir group and Telbivudine group with square test (P>0.05). Conclusions Entecavir and Telbivudine have no significant dfferences on patients with child-pugh scores，the rates of serum HBV-DNA undetectable and the rates of HBeAg seroconversion. But in Telbivudine group there were 3 patients with CK elevated, in Entecavir group there was no obvious daverse reaction. The treatment on child-pugh B grade patients with hepatitis B-induced cirrhosis was safe and effective with Entecavir and Telbivudine.